These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21854276)

  • 1. Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037).
    Trivedi MH; Greer TL; Potter JS; Grannemann BD; Nunes EV; Rethorst C; Warden D; Ring KM; Somoza E
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):339-49. PubMed ID: 21854276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial.
    Trivedi MH; Greer TL; Grannemann BD; Church TS; Somoza E; Blair SN; Szapocznik J; Stoutenberg M; Rethorst C; Warden D; Ring KM; Walker R; Morris DW; Kosinski AS; Kyle T; Marcus B; Crowell B; Oden N; Nunes E
    Trials; 2011 Sep; 12():206. PubMed ID: 21929768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials.
    Oden NL; VanVeldhuisen PC; Wakim PG; Trivedi MH; Somoza E; Lewis D
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):350-7. PubMed ID: 21854277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying and responding to trial implementation challenges during multisite clinical trials.
    Greer TL; Walker R; Rethorst CD; Northrup TF; Warden D; Horigian VE; Silverstein M; Shores-Wilson K; Stotts AL; Trivedi MH
    J Subst Abuse Treat; 2020 Mar; 112S():63-72. PubMed ID: 32220413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary outcome indices in illicit drug dependence treatment research: systematic approach to selection and measurement of drug use end-points in clinical trials.
    Donovan DM; Bigelow GE; Brigham GS; Carroll KM; Cohen AJ; Gardin JG; Hamilton JA; Huestis MA; Hughes JR; Lindblad R; Marlatt GA; Preston KL; Selzer JA; Somoza EC; Wakim PG; Wells EA
    Addiction; 2012 Apr; 107(4):694-708. PubMed ID: 21781202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and methodological considerations of an effectiveness trial of a computer-assisted intervention: an example from the NIDA Clinical Trials Network.
    Campbell AN; Nunes EV; Miele GM; Matthews A; Polsky D; Ghitza UE; Turrigiano E; Bailey GL; VanVeldhuisen P; Chapdelaine R; Froias A; Stitzer ML; Carroll KM; Winhusen T; Clingerman S; Perez L; McClure E; Goldman B; Crowell AR
    Contemp Clin Trials; 2012 Mar; 33(2):386-95. PubMed ID: 22085803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality assurance of research protocols conducted in the community: the National Institute on Drug Abuse Clinical Trials Network experience.
    Rosa C; Campbell A; Kleppinger C; Sampson R; Tyson C; Mamay-Gentilin S
    Clin Trials; 2009 Apr; 6(2):151-61. PubMed ID: 19342468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically relevant characteristics associated with early treatment drug use versus abstinence.
    Cochran G; Stitzer M; Nunes EV; Hu MC; Campbell A
    Addict Sci Clin Pract; 2014 Apr; 9(1):6. PubMed ID: 24708748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies.
    Korte JE; Magruder KM; Chiuzan CC; Logan SL; Killeen T; Bandyopadhyay D; Brady KT
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):358-66. PubMed ID: 21854278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: a summary of findings.
    Greenfield SF; Rosa C; Putnins SI; Green CA; Brooks AJ; Calsyn DA; Cohen LR; Erickson S; Gordon SM; Haynes L; Killeen T; Miele G; Tross S; Winhusen T
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):301-12. PubMed ID: 21854272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates and influences of alcohol use disorder comorbidity among primary stimulant misusing treatment-seekers: meta-analytic findings across eight NIDA CTN trials.
    Hartzler B; Donovan DM; Huang Z
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):460-71. PubMed ID: 21854291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network.
    Lindblad R; Hu L; Oden N; Wakim P; Rosa C; VanVeldhuisen P
    J Subst Abuse Treat; 2016 Nov; 70():73-80. PubMed ID: 27692192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conducting research with racial/ethnic minorities: methodological lessons from the NIDA Clinical Trials Network.
    Burlew AK; Weekes JC; Montgomery L; Feaster DJ; Robbins MS; Rosa CL; Ruglass LM; Venner KL; Wu LT
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):324-32. PubMed ID: 21854274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of NIDA CTN Protocol 0047: screening, motivational assessment, referral, and treatment in emergency departments (SMART-ED).
    Bogenschutz MP; Donovan DM; Adinoff B; Crandall C; Forcehimes AA; Lindblad R; Mandler RN; Oden NL; Perl HI; Walker R
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):417-25. PubMed ID: 21854285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIDA's Clinical Trials Network: an opportunity for HIV research in community substance abuse treatment programs.
    Tross S; Campbell AN; Calsyn DA; Metsch LR; Sorensen JL; Shoptaw S; Haynes L; Woody GE; Malow RM; Brown LS; Feaster DJ; Booth RE; Mandler RN; Masson C; Holmes BW; Colfax G; Brooks AJ; Hien DA; Schackman BR; Korthuis PT; Miele GM;
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):283-93. PubMed ID: 21854270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study.
    Trivedi MH; Greer TL; Rethorst CD; Carmody T; Grannemann BD; Walker R; Warden D; Shores-Wilson K; Stoutenberg M; Oden N; Silverstein M; Hodgkins C; Love L; Seamans C; Stotts A; Causey T; Szucs-Reed RP; Rinaldi P; Myrick H; Straus M; Liu D; Lindblad R; Church T; Blair SN; Nunes EV
    J Clin Psychiatry; 2017; 78(8):1075-1082. PubMed ID: 28199070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Site selection in community-based clinical trials for substance use disorders: strategies for effective site selection.
    Potter JS; Donovan DM; Weiss RD; Gardin J; Lindblad R; Wakim P; Dodd D
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):400-7. PubMed ID: 21854283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How practice and science are balanced and blended in the NIDA Clinical Trials Network: the bidirectional process in the development of the STAGE-12 protocol as an example.
    Donovan DM; Daley DC; Brigham GS; Hodgkins CC; Perl HI; Floyd AS
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):408-16. PubMed ID: 21854284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of study design to recruitment and retention in CTN trials.
    Wakim PG; Rosa C; Kothari P; Michel ME
    Am J Drug Alcohol Abuse; 2011 Sep; 37(5):426-33. PubMed ID: 21854286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.